Medical Indications for PrC-210
PrC-210 could be prescribed in more than 200 medical indications
Oxidative Stress and Ischemic Reperfusion Injury are the underlying cause for more than 200 medical diseases. Many of them have no medical treatment, and due to high mortality and enormous medical
costs, there is a high medical need to find a treatment option.
PrC-210 can become a viable treatment option for these diseases.
Delayed Graft Function (DGF) after Kidney Transplantation
Organ injury and damage from Oxidative Stress and Ischemia-Reperfusion are unavoidable consequences of kidney transplantations and are associated with a high rate of organ failure and patient mortality. They happen during ischemic time which can last up to 24 hours and during the reperfusion after implantation of the organ. During the transplantation process, the organ goes through ‘warm’ and ‘cold’ ischemic times, as shown in the chart below.
The short-term clinical symptom that illustrates the organ damage is defined as “Delayed Graft Function (DGF)”. Patients with Delayed Graft Function need dialysis during the first week after kidney transplantation to stabilize their kidney function. Delayed Graft Function is correlated with reduced organ survival and increased mortality of the organ recipient.
The PrC-210 Effect during Transplantation:
PrC-210 has been shown in animal experiments to reduce cellular death in
transplanted kidneys to the same level seen in
normal non-transplanted kidneys during
both cold ischemic time and reperfusion
time.
The complete scavenging and capture of Free Radicals by PrC-210 and complete
inhibition of cellular death led to significant reduction of
renal tubular cell damage during 30 hours Cold
Ischemia and total cell protection during
Reperfusion.
Based upon the compelling Kidney transplant animal data, PrC-210 will be
administered during the entire transplantation
process in order to protect the transplant organ
from the donor to the recipient.
If organ damage is reduced, the
♦ organ survival time will be increased, and
♦ the recipient mortality will be reduced.
♦ This will lead to a reduction of second and
third organ transplantations and to a reduced
number of patients on the waiting list and
thereby shortens the time to organ transplantation.
The average time on the waiting list per kidney is
between 2 and 8 Years.
There is currently still no approved drug for the prevention of DGF.
Alzheimer’s Disease
Current research in Alzheimer’s has moved away from β-amyloid deposition as the primary patho-mechanism, rather,
Mitochondrial dysfunction and associated Reactive Oxygen stress leading to cell death more closely correlates with the onset and clinical course of non-familial (non-inherited) Alzheimer’s, which accounts for >95% of human Alzheimer’s cases.
Chronic, bi-weekly PrC-210 doses are a logical strategy to deal with this newly emergent Alzheimer’s patho-mechanism.
Acute Radiation Syndrome (ARS)
Increasing risks of radiological and nuclear accidents, such as Chernobyl and Fukushima, terrorist attacks or a new nuclear armament are driving interest in developing radiation countermeasures to potentially injurious exposures to radiation. There is no compound approved that is able to prevent Acute Radiation Syndrome when given ahead of, or after, a nuclear or radiation event. PrC‑210 given before deadly 9Gy radiation showed 100% protection of DNA and 100% survival of rats and mice after 30 days. The graph shows 100% mice survival with PrC-210 given 30 minutes before deadly total body radiation. This indicates, that PrC‑210 can be a protective agent against high‑and low linear energy transfer radiation exposure and would save many human lives.
